By Professor Michael Leonard Friedlander

Conference Papers

Ang JE; Gourley C; High HA; Shapira-Frommer R; Powell CB; Castonguay V; De Greve J; Yap TA; Fong PCC; Olmos D; Banerjee SN; Chen L-M; Friedlander M; Kaufman B; Oza AM; De Bono JS; Gore ME; Kaye SB, 2012, 'Use of chemotherapy (CT) in BRCA1/2-deficient ovarian cancer (BDOC) patients (pts) with poly-ADP-ribose polymerase inhibitor (PARPi) resistance: A multi-institutional study', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2012 - 06 June 2012, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000318009803479&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Park SB; Lin CSY; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC, 2011, 'A Novel Approach to the Emerging and Frequent Problem of Sustained Long-term Oxaliplatin-induced Neurotoxicity', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, SWEDEN, Stockholm, pp. S436 - S436, presented at European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, SWEDEN, Stockholm, 23 September 2011 - 27 September 2011, http://dx.doi.org/10.1016/S0959-8049(11)71792-0

Bennett BK; Goldstein D; Friedlander M; Park SB; Kiernan MG, 2011, 'Oxaliplatin-induced Neurotoxicity - Comparing Four Methods of Assessment', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, SWEDEN, Stockholm, pp. S234 - S234, presented at European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, SWEDEN, Stockholm, 23 September 2011 - 27 September 2011, http://dx.doi.org/10.1016/S0959-8049(11)71114-5

Alsop K; Fereday S; Meldrum C; deFazio A; Webb P; Birrer MJ; Friedlander M; Fox SB; Bowtell D; Mitchell G, 2011, 'Germ-line BRCA mutations in high-grade ovarian cancer: A case for routine BRCA mutation screening after a diagnosis of invasive ovarian cancer', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.5026

Friedlander M; Stockler MR; King M; Oza AM; Voysey M; Martyn J; Gillies K; Sjoquist KM; Butow P, 2011, 'Measuring subjective improvement as well as objective response to estimate the benefit of palliative chemotherapy in women with platinum-resistant or -refractory ovarian cancer: The symptom benefit study (ANZGOG-0701/GCIG/PoCoG).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.tps241

Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote IB; Rustin GJS; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Macpherson E; Watkins C; Carmichael J; Matulonis U, 2011, 'Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.5003

Harvey S; Milne RL; Birch KE; Weideman P; McLachlan S; Friedlander M; Goldgar D; Hopper JL; Phillips K, 2011, 'Prospective study of breast cancer risk in mutation-negative women from BRCA1 or BRCA2 mutation-positive families in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.1516

Phillips K; Milne RL; Rookus MA; Goldgar D; Friedlander M; McLachlan S; Buys SS; Antoniou AC; Birch KE; Terry MB; Easton D; Weideman P; Daly MB; Andrieu N; John EM; Hooning M; Andrulis IL; Caldes T; Olsson H; Hopper JL, 2011, 'Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers: A combined analysis from the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), the International BRCA1 and BRCA2Carrier Cohort Study (IBCCS), and the Breast Cancer Family Registry (BCFR).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.1500

Stuart GCE; Kitchener H; Bacon M; DuBois A; Friedlander M; Ledermann J; Marth C; Thigpen T; Trimble E, 2011, '2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: Report from the fourth ovarian cancer consensus conference', in International Journal of Gynecological Cancer, pp. 750 - 755, http://dx.doi.org/10.1097/IGC.0b013e31821b2568

Houghton BB; Grimison PS; Toner GC; Chatfield M; Thomson DB; Friedlander M; Gebski V; Rosenthal M; Gurney H; Stockler M, 2011, 'The effect of pulmonary function testing on bleomycin dosing in germ cell tumors', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2011.29.7_suppl.227

Watts KJ; Meiser B; Conlon H; Rovelli S; Tiller K; Zorbas H; Lewis C; Neil G; Friedlander M, 2010, 'Implementation and evaluation of a new specialist breast care nurse role for women with metastatic breast cancer', in Asia-Pacific Journal of Clinical Oncology, Blackwell Publishing Asia, Australia, presented at Clinical Oncological Society of Australia 37th Annual Scientific Meeting, Melbourne, 09 November 2010 - 12 November 2010

Lemech CR; Cosman R; Lee C; Friedlander M; Lewis C; Lynch J; Thomas D; Clingan P; Glasgow A, 2010, 'Cardiac dysfunction in patients receiving trastuzumab for early stage breast cancer in the SESIAHS', in Aisa-Pacific Journal of Clinical Oncology, Medical Oncology Group of Australia Annual Scientific Meeting, Sydney Australia, presented at Medical Oncology Group of Australia Annual Scientific Meeting, Sydney Australia, 12 August 2010 - 14 August 2010, http://onlinelibrary.wiley.com/doi/10.1111/j.1743-7563.2010.01301.x/epdf

Lee CK; Guardiola E; Hogberg T; Friedlander M; Bentley J; Denison U; Vergote IB; Pisano C; Parma G; Wimberger P, 2010, 'Development of a nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer based on the CALYPSO trial', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2010.28.15_suppl.5105

Park SB; Lin CS-Y; Krishnan AV; Friedlander M; Lewis C; Kiernan MC, 2010, 'Pathophysiology of paclitaxel-induced neurotoxicity', in Small D (ed.), Australian Neurosciences Society Annual Scientific Meeting 2010, ANS, Sydney, pp. 160 - 160, presented at Australian Neurosciences Society Annual Scientific Meeting 2010, Sydney, 31 January 2010 - 03 February 2010

Webber K; Goldstein D; Bennett BK; Boyle F; De Souza PL; Wilken N; Friedlander M; Lloyd AR, 2010, 'Late fatigue after adjuvant therapy for early breast cancer is largely unrelated to cancer or its treatment: 5 year follow-up of a prospective cohort study', in Asia-Pacific Journal of Clinical Oncology, Blackwell Publishing Asia Pty Ltd, Australia, pp. 53 - 60, presented at ., -

Bennett BK; Goldstein D; De Souza PL; Wilken N; Friedlander M; Hickie IB; Scott E; Rogers N; Lloyd AR, 2010, 'What part does sleep disturbance play in post-cancer fatigue? Findings from a prospective cohort study', in Journal of Clinical Oncology, American Society of Clinical Oncology, United States, pp. 93s

Kiely BE; Jenkins MA; McKinley JM; Friedlander ML; Weideman PC; Milne R; McLachlan S; Hopper JL; Phillips K, 2009, 'Contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, presented at 45th Annual Meeting of the American-Society-of-Clinical-Oncology, FL, Orlando, 29 May 2009 - 02 June 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000276606602105&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Audeh MW; Penson RT; Friedlander M; Powell B; Bell-McGuinn KM; Scott C; Weitzel JN; Carmichael J; Tutt A, 2009, 'Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, presented at 45th Annual Meeting of the American-Society-of-Clinical-Oncology, FL, Orlando, 29 May 2009 - 02 June 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000276606600002&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Tutt A; Robson M; Garber JE; Domchek S; Audeh MW; Weitzel JN; Friedlander M; Carmichael J, 2009, 'Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, presented at 45th Annual Meeting of the American-Society-of-Clinical-Oncology, FL, Orlando, 29 May 2009 - 02 June 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000276607000010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Goodwin P; Phillips K; West D; Ennis M; Hopper J; John EM; O'Malley F; Milne R; Andrulis I; Friedlander M; Longacre T, 2009, 'Prognosis in BRCA1, BRCA2 associated breast cancer (BC): a prospective Breast Cancer Family Registry (BCFR) international population-based cohort study.', in Cancer Research, American Association for Cancer Research (AACR), pp. 2072 - 2072, http://dx.doi.org/10.1158/0008-5472.sabcs-2072

Goodwin P; Phillips KA; West DJ; Ennis M; Hopper JL; John E; O Malley F; Milne RS; Andrulis I; Friedlander ML; Longacre T, 2009, 'Prognosis in BRCA1, BRCA2 associated breast cancer (BC): a prospective Breast Cancer Family Registry (BCFR) international population-based cohort study', in Cancer research, American Association Cancer Research, Philadelphia, PA, pp. 178S - 178S, presented at 31st Annual San Antonio Breast Cancer Symposium, San Antonio, TX, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000262583200363&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Friedlander M; Hancock KC; Benigno B; Rischin D; Messing M; Stringer CA; Hodge JP; Ma B; Matthys G; Lager JJ, 2008, 'PAZOPANIB (GW786034) IS ACTIVE IN WOMEN WITH ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE AND PERITONEAL CANCERS: RESULTS OF A PHASE II STUDY', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SWEDEN, Stockholm, pp. 211 - 211, presented at 33rd European-Society-for-Medical-Oncology Congress, SWEDEN, Stockholm, 12 September 2008 - 16 September 2008, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000259973300662&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Field KM; Phillips K; Jenkins MA; McKinley J; Weideman P; Price M; Friedlander M; McLachlan S; Lindeman G; Butow P, 2008, 'Complementary and alternative medicine (CAM) use in high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2008.26.15_suppl.1528

Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander M; Kiernan MC, 2008, 'Early detection of oxaliplatin-induced neurotoxicity: Getting it before it hurts', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2008.26.15_suppl.15015

Friedlander M, 2008, 'Medical Oncology Group of Australia (MOGA)/Novartis cancer achievement award', in Cancer Forum, pp. 27 - 31

Bennett BK; Goldstein D; Friedlander ML; Boyle F; De Souza PL; Wilken N; Hickie IB; Scott E; Lloyd AR, 2008, 'A prospective cohort study of fatigue after adjuvant therapy for breast cancer', in Psycho - Oncology, John Wiley & Sons Ltd, Chichester, W Sussex, England, pp. S36 - S37, presented at Psycho-Oncology 2008, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000257874200071&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Friedlander M; Hancock KC; Benigno B; Rischin D; Messing M; Stringer CA; Tay EH; Kathman S; Matthys G; Lager JJ, 2007, 'Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: Initial results of a phase II study', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000455043701341&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Peate ML; Meiser B; Hickey MS; Thewes B; Butow PN; Saunders C; Rovelli S; Zorbas H; Friedlander ML, 2007, 'Breast cancer and fertility: Making hard choices easier - The development and evaluation of fertility-related decision aid for young women with early breast cancer', in Psycho - Oncology, John Wiley & Sons Ltd, Chichester, W Sussex, England, pp. S15 - S16, presented at Psycho-Oncology 2007

Dawson S; McKinley J; Jenkins M; McLachlan S; Lindeman G; Friedlander M; Hopper J; Phillips K, 2006, 'Cancer risk management practices of non-carriers within BRCA1/2 mutation positive families in the Kathleen Cunningham Consortium for Research into Familial Breast Cancer (kConFab).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, GA, Atlanta, pp. 53S - 53S, presented at 42nd Annual Meeting of the American-Society-of-Clinical-Oncology, GA, Atlanta, 02 June 2006 - 06 June 2006, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000239009400210&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Thigpen T; Stuart G; du Bois A; Friedlander M; Fujiwara K; Guastalla JP; Kaye S; Kitchener H; Kristensen G; Mannel R; Meier W; Miller B; Poveda A; Provencher D; Stehman F; Vergote I, 2005, 'Clinical trials in ovarian carcinoma: Requirements for standard approaches and regimens', in Annals of Oncology, http://dx.doi.org/10.1093/annonc/mdi962

Mitchell P; Goldstein D; Michael M; Beale P; Friedlander M; Zalcberg J; Clarke S; White S, 2005, 'Addition of gabapentin (G) to a modified FOLFOX regimen does not reduce neurotoxicity in patients (pts) with advanced colorectal cancer (CRC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, pp. 266S - 266S, presented at 41st Annual Meeting of the American-Society-of-Clinical-Oncology, FL, Orlando, 13 May 2005 - 17 May 2005, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000230326601475&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Friedlander ML; Bishop J; Levi J; Zalcberg JR; Olver IN; Smith JV; Toner GC, 2005, 'A phase II trial of Paclitaxel in previously treated patients with metastatic breast cancer.', in Medical Journal of Australia, Australasian Med Publishing Company Ltd, Sydney, NSW, Australia, pp. 520 - 523, presented at Medical Journal of Australia

Thewes B; Meiser B; Duric V; Stockler M; Friedlander M, 2004, 'What survival benefits do pre-menopausal early breast cancer patients consider necessary to make endocrine therapy worthwhile?', in PSYCHO-ONCOLOGY, JOHN WILEY & SONS LTD, pp. S40 - S41, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000223957800084&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Aghmesheh M; Friedlander M; Russell PJ; Edwards L; Yang JL; Kconfab K; Nesland JM; Danielson H; Kaern J; Tucker KM, 2004, 'BRCA1 mutation site may associate with nuclear DNA content in BRCA1-associated ovarian carcinomas.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, LA, New Orleans, pp. 459S - 459S, presented at 40th Annual Meeting of the American-Society-of-Clinical-Oncology, LA, New Orleans, 05 June 2004 - 08 June 2004, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000223512401819&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Loi S; Milne RL; Friedlander ML; McCredie MRE; Giles GG; Hopper JL; Phillips KA, 2004, 'The impact of obesity on outcomes in a population-based cohort of women with early-onset breast cancer.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, LA, New Orleans, pp. 845S - 845S, presented at 40th Annual Meeting of the American-Society-of-Clinical-Oncology, LA, New Orleans, 05 June 2004 - 08 June 2004, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000223512403351&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Thewes B; Meiser B; Rickard J; Friedlander M, 2003, 'The fertility and menopause related information needs of younger women with a diagnosis of breast cancer', in PSYCHO-ONCOLOGY, JOHN WILEY & SONS LTD, pp. S125 - S125, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000183225400153&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Aghmesheh M; Edwards L; Clarke CL; Russell PJ; Friedlander ML; Tucker K; Defazio A, 2002, 'Steroid hormone receptor expression in heriditary and sporadic ovarian cancers', in Proceedings of the American Association for Cancer Research, American Association Cancer Research, Philadelphia, PA, USA, pp. 6 - 6, presented at 93rd Annual Meeting of the AACR, San Francisco, California USA, 06 April 2002 - 10 April 2002

Apicella C; Andrews L; Tucker K; Bankier A; Friedlander M; Venter D; Hopper J, 1999, 'Australian Jewish women's experiences with a breast cancer gene testing program as part of the co-operative family registry for breast cancer studies (CFR-BCS).', in AMERICAN JOURNAL OF HUMAN GENETICS, UNIV CHICAGO PRESS, pp. A191 - A191, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000082879801051&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Links M; Friedlander M; Russell P, 1999, 'Enhancement of cisplatin cytotoxicity by caffeine does not correlate with abrogation of G2 arrest.', in BRITISH JOURNAL OF CANCER, CHURCHILL LIVINGSTONE, pp. 42 - 42, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000081955000151&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Bishop DT; Rapley E; Tucker K; Collins F; Donald J; Friedlander M; Peng HQ; Goss P; Hogg D; Easton DF; Teare D; Crockford G; Forman D; Leahy M; Bodmer JG; Moses J; Tonks S; Oliver RTD; Biggs P; Seal S; Barfoot R; Gill S; Patel S; Hamoudi R; Hunter R; Thomlinson I; Cooper C; Stratton M; Huddart R; Fosså SD; Heimdal K, 1998, 'Candidate regions for testicular cancer susceptibility genes: The International Testicular Cancer Linkage Consortium', in APMIS, pp. 64 - 72, http://dx.doi.org/10.1111/j.1699-0463.1998.tb01320.x

Friedlander M; DeGramont A; Millward MJ; Bell D; Bugat R; Harnett P; Moreno JA; Campbell L; Ripoche V; Kayitalire L, 1997, 'Activity of Gemcitabine in stage 3 or 4 ovarian cancer: Patients previously treated with cisplatin (CP)-containing regimens', in EUROPEAN JOURNAL OF CANCER, PERGAMON-ELSEVIER SCIENCE LTD, pp. 538 - 538, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1997XX83000533&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Rapley E; Tucker K; Collins F; Donald J; Friedlander M; Peng HQ; Goss P; Hogg D; Easton DF; Teare D; Bishop DT; Crockford G; Forman D; Leahy M; Bodmer JG; Moses J; Tonks S; Oliver RTD; Biggs P; Seal S; Barfoot R; Gill S; Patel S; Hamoudi R; Hunter R; Thomlinson I; Cooper C; Stratton M; Huddart R; Fossa SD; Heimdal K, 1997, 'Candidate regions for testicular cancer susceptibility genes', in APMIS, WILEY, DENMARK, COPENHAGEN UNIV HOSP, COPENHAGEN, pp. 64 - 70, presented at 4th Copenhagen Workshop on Carcinoma In Situ and Cancer of the Testis - Molecular and Endocrine Aspects, DENMARK, COPENHAGEN UNIV HOSP, COPENHAGEN, 18 May 1997 - 21 May 1997, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000072338300014&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Zalcberg JR; Bishop JF; Millward MJ; Zimet A; Laird J; Barter C; Seward D; McKeage MJ; Friedlander ML; Toner G; Berille J; Blanc C, 1995, 'Interim results of a phase II trial of docetaxel in combination with cisplatin in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC)', in EUROPEAN JOURNAL OF CANCER, PERGAMON-ELSEVIER SCIENCE LTD, pp. 1084 - 1084, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1995TH91901079&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

FRIEDLANDER ML; MUSGROVE L; RUSSELL P; TOPPLIA M; HEDLEY D; TAYLOR IW; TATTERSALL MHN, 1983, 'FLOW CYTOMETRIC ANALYSIS OF DNA CONTENT IN OVARIAN-CANCER', in CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, BLACKWELL SCIENCE, pp. 489 - 489, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1983RB75800115&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Back to profile page